Effer-K Orange 977.5 mg/1
POTASSIUM BICARBONATE · TABLET, EFFERVESCENT · Nomax Inc.
Effer-K Orange is a tablet, effervescent containing potassium bicarbonate at 977.5 mg/1, taken oral. Manufactured by Nomax Inc..
Key Facts
- Brand Name
- Effer-K Orange
- Generic Name
- POTASSIUM BICARBONATE
- NDC Code (Product)
51801-001- Manufacturer
- Nomax Inc.
- Strength
- 977.5 mg/1
- Dosage Form
- TABLET, EFFERVESCENT
- Route
- ORAL
- Marketing Status
- Marketing Start
- 01/30/2013
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Full Prescribing Information
Indications & Usage
Indications and Usage For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in chronic digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. For prevention of potassium depletion when the dietary intake of potassium ion is inadequate in the following conditions; patients receiving digitalis and diuretics for congestive heart failure; hepatic cirrhosis with ascites; states of aldosterone excess with normal renal function; potassiumlosing nephropathy, and certain diarrheal states; long-term corticosteroid therapy. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension or receiving certain antibiotics is often unnecessary when such patients have a normal dietary pattern. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases supplementation with potassium salts may be indicated.
Dosage & Administration
Dosage and administration Dosage and Administration: Adults- One Effer-K ® flavored tablet, (Orange, Lemon Citrus or Cherry Berry) each containing 25 mEq (978 mg) of potassium, completely dissolved in 4 ounces of cold or ice water, 1 to 4 times daily, depending on the requirement of the patient. For Effer-K ® unflavored tablets (each containing 25 mEq (978 mg) of potassium) we recommend completely dissolving one tablet in 12 to 16 ounces of cold juice of the patient's choice. NOTE: It is suggested that any effervescent potassium tablets be taken with meals and sipped slowly over a 5 to 10 minute period.
Warnings
Warnings In patients with hyperkalemia and impaired mechanisms for excreting potassium the administration of potassium salts can produce hyperkalemia and cardiac arrest. This occurs most commonly in patients given potassium by the intravenous route but may also occur in patients given potassium orally. Potentially fatal hyperkalemia can develop rapidly and be asymptomatic. The use of potassium salts in patients with chronic renal disease, or any other condition which impairs potassium excretion, requires particularly careful monitoring of the serum potassium concentration and appropriate dosage adjustment. Note: There is no conclusive evidence that potassium supplements lower blood pressure in hypertensive patients.
Contraindications
Contraindications Potassium supplements are contraindicated in patients with hyperkalemia since a further increase in serum potassium concentration in such patients can produce cardiac arrest. Conditions predisposing to hyperkalemia include: chronic renal failure, acute metabolic acidosis, uncontrolled diabetes mellitus, esophageal compression or delayed gastric emptying or intestinal obstruction/stricture or peptic ulcer. Potassium supplements should be used with caution and only where medically indicated in patients with familial periodic paralysis, myotonia congenita or severe/complete heart block. IMPORTANT: Potassium supplements are contraindicated in patients receiving potassium-sparing diuretics (e.g. spironolactone, triamterene) since such use may produce severe hyperkalemia.
Drug Interactions
Drug Interactions The simultaneous administration of potassium supplements and a potassium-sparing diuretic can produce severe hyperkalemia (see Contraindications ). Potassium supplements should be used cautiously in patients who are using salt substitutes, because most of the latter contain substantial amounts of potassium. Such concomitant use could result in hyperkalemia. Moreover, the following drugs may produce unfavorable interactions when used concomitantly with potassium supplements: angiotension-converting enzyme (ACE) inhibitors, nonsteroid anti-inflammatory drugs (NSAIDs), beta-adrenergic blocking drugs, heparin, low-salt foods, other potassium containing medications, digitalis glycosides and others.
Adverse Reactions
Adverse Reactions One of the most severe adverse effects is hyperkalemia (see Contraindications , Warnings and Overdosage ). The most common adverse reactions to oral potassium salts are nausea, vomiting, abdominal discomfort, and diarrhea. These symptoms are due to irritation of the gastrointestinal tract and are best managed by diluting the preparation further, taking the dose with meals, or reducing the dose. Skin rash has been reported rarely.
Frequently Asked Questions
What is Effer-K Orange used for?
Effer-K Orange contains POTASSIUM BICARBONATE. It is a tablet, effervescent taken oral. Consult your doctor for specific uses.
Is Effer-K Orange a controlled substance?
Effer-K Orange is not classified as a controlled substance by the DEA.
What is the generic name for Effer-K Orange?
The generic name for Effer-K Orange is POTASSIUM BICARBONATE. There are 8 other brand versions of POTASSIUM BICARBONATE.
What is the NDC code for Effer-K Orange 977.5 mg/1?
The NDC (National Drug Code) for Effer-K Orange 977.5 mg/1 is 51801-001, listed by Nomax Inc..
Other Potassium Brands
See all →- Effer-K 10 mEq Cherry Vanilla391 mg/151801-014
- Effer-K 20 mEq Unflavored782 mg/151801-011
- Effer-K Lemon Citrus977.5 mg/151801-005
- Effer-K 20 mEq Orange Cream782 mg/151801-012
- KLOR-Con/EF978 mg/10245-5326
- Effer-K 10 mEq Unflavored391 mg/151801-013
- Effer-K Unflavored977.5 mg/151801-007
- Effer-K Cherry Berry977.5 mg/151801-006
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)